Physician profile
Randall S Fenner
NPI 1073780375
$1,548.79
in general payments reported to CMS, 2019-2025
23 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $118 · 2021: $254 · 2022: $226 · 2023: $153 · 2024: $185 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $284.53 | 2019-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $230.41 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $159.13 | 2019-2024 | Ozempic, Rybelsus |
| Medtronic, INC. | $136.20 | 2021-2024 | Minimed 780g |
| Insulet Corporation | $96.97 | 2019-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.14 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $68.53 | 2019-2021 | |
| Abbott Laboratories | $68.41 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Regeneron Healthcare Solutions, INC. | $60.24 | 2019 | |
| Medtronic Minimed, INC. | $51.01 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $50.47 | 2019-2023 | |
| Kyowa Kirin, INC. | $42.63 | 2023-2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $37.55 | 2019 | |
| Chiesi USA, INC. | $26.40 | 2025 | Mycapssa |
| Radius Health, INC. | $25.30 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $24.70 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $21.49 | 2019 | |
| Ibsa Pharma INC. | $16.38 | 2023 | Tirosint, Licart |
| Sequel Med Tech, LLC | $16.27 | 2025 | Twiist |
| Pfizer INC. | $14.31 | 2022 | |
| Horizon Therapeutics Plc | $13.33 | 2022 | |
| Recordati_rare_diseases_inc. | $12.70 | 2022 | |
| Eusa Pharma (US) LLC | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Fenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.